<DOC>
	<DOCNO>NCT00019084</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell mixed tumor protein may make body build immune response kill tumor cell . Interleukin-2 may stimulate person 's white blood cell kill tumor cell . Combining vaccine therapy interleukin-2 may effective treatment advance cancer . PURPOSE : Phase II trial study effectiveness vaccine make patient ' white blood cell mixed tumor protein treat patient advanced cancer .</brief_summary>
	<brief_title>Vaccine Therapy Biological Therapy Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether endogenous cellular immunity particular tumor-specific mutate p53 ra protein present patient tumor express mutant p53 ra . II . Determine whether vaccination antigen-presenting cell pulse vitro synthetic peptide correspond tumor 's p53 ra mutation presence sargramostim ( GM-CSF ) induce boost patient cellular immunity mutate peptide patient population . III . Assess type characteristic cellular immunity generate . IV . Determine whether vivo-primed T-cells generate p53 ra mutation , expand vitro correspond peptide , infuse subcutaneous interleukin-2 enhance activity specific cytotoxic T-lymphocyte immune response and/or tumor response patient . OUTLINE : Patients assign 1 2 treatment regimen . The first 5 patient accrue assigned Regimen A . Three week 5 patient enrol , additional patient accrue assigned Regimen B . All patient undergo peptide hypersensitivity test peptide treat prior vaccination . Regimen A : Two day prior vaccination , peripheral blood mononuclear cell ( PBMC ) harvest . PBMC incubate 48 hour either patient-specific mutant p53 ra peptide fragment sargramostim ( GM-CSF ) . The antigen-presenting cell ( APC ) irradiate prior use . APC reinfused day 0 . Treatment repeat 3 week every 6 week total 4 vaccination . Regimen B : Patients vaccinate APC Regimen A. PBMC harvest prior first APC vaccination 1 week second , third , fourth APC vaccination . PBMC incubate 7 day either peptide patient vaccinate ( mutant p53 ra peptide fragment ) interleukin-2 ( IL-2 ) . The peptide-activated lymphocyte ( PAL ) reinfused 1 hour 2 week APC vaccination . Patients receive IL-2 subcutaneously 5 day week 2 week begin 4 hour PAL infusion . Patients regimens stable respond disease continue treatment every 6 week . Patients achieve complete response continue treatment 1 additional year . Patients follow 1 2 month . PROJECTED ACCRUAL : A maximum 70 patient ( 5 per Regimen A , 28-65 per Regimen B ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose advanced cancer consider incurable standard therapy express mutant p53 ra , e.g . : Lung Pancreatic Breast Colon Cervical Ovarian p53 ra mutation point mutation , insertion , deletion proteincoding sequence Tumor tissue require p53 ra mutation determination ( paraffin block fresh tissue ) Availability tumor tissue cell line preparation tumor lymph node tissue tumorinfiltrating lymphocyte expansion desire No history CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : More 3 month Hematopoietic : WBC least 2,000/mm3 Lymphocyte count least 800/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL ALT great 4 time normal No hepatitis B C Renal : Creatinine great 2.0 mg/dL Cardiovascular : No myocardial infarction within 6 month No New York Heart Association class III IV heart disease Immunologic : HIV negative No autoimmune disease , e.g . : Systemic lupus erythematosus Multiple sclerosis Ankylosing spondylitis Responsive skin antigens Other : No weight loss great 20 % last 6 month No active infection require antibiotic No active second malignancy except basal cell skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : At least 4 week since prior chemotherapy recover Endocrine therapy : At least 4 week since prior steroid recover Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>